Combioxin is a clinical-stage biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections.
The company entered into worldwide licensing agreement with Eagle Pharmaceuticals for the commercial rights to its pipeline.
CAL02
Novel first-in-class anti-toxin agent being developed for the treatment of severe community-acquired bacterial pneumonia.
The unique therapeutic approach of CAL02 consists in using liposomes engineered to neutralize virulence effectors playing a critical role in the development of organ failure and fatal complications in severe infections.
Received FDA Fast-Track and Qualified Infectious Disease Product (QIDP) designations.
Global Phase 2 clinical study underway.
FDA grants Qualified Infectious Disease Product (QIDP) and Fast-Track Designations for CAL02
June 13, 2023
Pneumonia is the most common infection requiring hospitalization and admission to the intensive care unit (ICU), and is the third most common cause of death globally with 2.4 million deaths per year
There are >300 million cases per year
2’400 / day
CHILDREN < 5 YEARS DYING
OF PNEUMONIA
2.4 million
DEATHS CAUSED ANNUALLY
BY PNEUMONIA
Up to 50%
MORTALITY RATES OF
SEVERE PNEUMONIA
FOUNDING MEMBERS
Samareh Azeredo da Silveira
Managing Director
Frédéric Lajaunias
Managing Director